Page 147 WHO - Guidelines on the pharmacological treatment of persisting pain in children with medical illness

Mariela Bertolino, declared having received US$ 5000 in a 2-year period from Archimedes Pharma
Limited for a multicenter study of long-term safety on the use of fentanyl in the treatment of
breakthrough cancer pain in adults.

Allen Finley declared being involved in research supported by several grants from the Canadian
Institutes of Health Research, none of which entailed a personal financial benefit. He also declared his
role as past-President of the Special Interest Group on Pain in Childhood of the International Association
of Study of Pain (IASP). He declared having received US$ 3500 for technical consultation on study
design for tramadol from Johnson & Johnson.

Henry Lu declared that he was technical adviser for pregabalin, marketed by Pfizer, in the Philippines.
Pregabalin was not included among the medicines considered for clinical recommendations in these
guidelines.

Rajat Ray declared having received support for post-marketing surveillance on Addnok-N (the
combination of buprenorphine and naloxone) marketed by Rusan Pharma Ltd., India. Buprenorphine
in combination with naloxone was not included among the medicines considered for clinical
recommendations in these guidelines.

The other members of the Guidelines Development Group reported no conflicts of interest.

The GDG meeting was facilitated by Andy Gray and Nicola Magrini. Andy Gray reported being a Member
of the Scheduling and Naming Expert Committee of the South African Medicines Control Council
and trustee (Director) of LIFELab, the East Coast Biotechnology Regional Innovation Centre Trust, a
government funding agency for biotechnology. LIFELab is not developing or producing any medicines
considered for clinical recommendations in these guidelines. Both consultants reported no conflicts of
interest.

Management of potential conflicts of interest of the members of the Guidelines Development Group

Allen Finley did not participate in a final decision on any recommendations related to tramadol.
Mariela Bertolino did not participate in a final decision on any recommendations related to fentanyl.

Declaration of interest of the external reviewers
Rosa Buitrago reported being Product Patrimony Manager for Sanofi-Aventis in Panama from October
2007 to September 2010. No current interests reported.

Stuart MacLeod reported being the Director of the Child and Family Research Institute at British
Columbia Children’s Hospital from 2003 to January 2010. The institute has received around US$ 50 000
for research on pain from the private sector. No current interests reported.

Gary Walco reported having received payments from pharmaceutical companies for consultancies. These
amounted to approximately: US$ 6500 from Purdue Pharma and US$ 2500 from Pfizer in 2010;

> 144